N-Acetyl Semax Amidate: Variants and Analogs in Research
N-Acetyl Semax Amidate is the most proteolytically stable Semax analog in the published research literature. This page documents the structural differences, stability data, and research context for all three main analogs.
N-Acetyl Semax Amidate: Variants and Analogs in Research
N-Acetyl Semax Amidate is the most proteolytically stable form of the Semax compound family in the published research literature.[17][18] The three main analogs — Semax, N-Acetyl Semax, and N-Acetyl Semax Amidate — share the core heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro) but differ in N-terminal and C-terminal modifications that substantially affect enzymatic degradation rates.
Understanding these structural differences requires a brief account of how peptides are degraded in biological media. Two enzyme classes are primarily responsible for Semax catabolism: aminopeptidases, which cleave from the N-terminus (the Met end), and carboxypeptidases, which cleave from the C-terminus (the terminal Pro end). Modifications that block either terminus slow the corresponding enzyme class — extending the effective duration of peptide activity in biological systems.[17][18]
Semax vs N-Acetyl Semax vs N-Acetyl Semax Amidate
What is the difference between Semax, N-Acetyl Semax, and N-Acetyl Semax Amidate? N-acetylation and C-terminal amidation improve enzymatic stability and CNS penetration; studies suggest amidated variants have longer effective half-lives in plasma.[17][18]
Semax (parent compound). The unmodified heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. The free N-terminal methionine is subject to aminopeptidase cleavage; the free C-terminal proline is subject to carboxypeptidase cleavage. The parent peptide has a plasma half-life of approximately 2-5 minutes under typical serum enzyme activity. Despite this short half-life, downstream neurotrophin signaling extends effects substantially beyond clearance.[9]
N-Acetyl Semax. An acetyl group is added to the N-terminal methionine (Ac-Met-Glu-His-Phe-Pro-Gly-Pro). Shevchenko et al. (2013) examined the stability of N-Acetyl Semax to aminopeptidase and microsomal enzyme pathways and demonstrated that N-acetylation reduces N-terminal aminopeptidase susceptibility.[18] The C-terminus remains unmodified and subject to carboxypeptidase activity. Net result: slower N-terminal degradation, unchanged C-terminal degradation — a partial stability improvement.
N-Acetyl Semax Amidate. Both N-terminal acetylation and C-terminal amidation (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2). Shevchenko et al. (2013) showed that structural modifications at the N-terminus with various amino acids affected carboxypeptidase-mediated proteolysis rates, providing the basis for developing more proteolytically stable analogs.[17] C-terminal amidation blocks carboxypeptidase cleavage of the terminal proline. Combining both modifications produces a peptide resistant to both major degradation pathways — the longest plasma stability among the three forms.
Proteolytic stability data
Two Shevchenko et al. (2013) studies published in Doklady Biological Sciences provide the primary experimental basis for the stability hierarchy among Semax analogs.[17][18]
The first study examined carboxypeptidase-mediated proteolysis of Semax analogs with different N-terminal amino acids, demonstrating that N-terminal modifications alter degradation rates in a predictable manner.[17] The study provides the biochemical rationale for N-Acetyl Semax as a more stable analog without requiring full C-terminal modification.
The second study characterized the stability of Semax acetyl (N-acetylated Semax) specifically in biological media — examining leucyl aminopeptidase and microsomal enzyme pathways — and provided comparative proteolytic stability data between acetylated and non-acetylated forms across different biological matrices.[18]
Neither study characterized N-Acetyl Semax Amidate's stability directly in these assays; the amidated form's predicted stability advantage is extrapolated from the cumulative effect of N-terminal acetylation (documented in [18]) and C-terminal amidation (which blocks carboxypeptidase activity on the free C-terminal proline, documented indirectly in [17]).
For a discussion of intranasal pharmacokinetics and how peptide half-life translates to CNS exposure duration, see intranasal vs subcutaneous administration and Semax storage and stability.
Research context for Semax analog selection
The selection of Semax analog in any given research study affects the pharmacokinetic profile and, consequently, the dose-response relationship. Studies using the parent peptide at 50-250 µg/kg intranasal[1][2] are not directly comparable to hypothetical studies using N-Acetyl Semax Amidate at equivalent concentrations, because the acetylated/amidated form would persist longer at active concentrations in biological media.
The existing Semax literature — BDNF upregulation, ischemia neuroprotection, behavioral studies — was conducted primarily with the parent compound. The N-acetyl and amidated analogs have been characterized structurally and for proteolytic stability[17][18] but have not been the primary compound in published efficacy studies of comparable scope.
Consequently, the mechanistic and efficacy findings documented on this site — BDNF upregulation, MC4R binding, ischemia neuroprotection, monoamine modulation — all derive from parent-Semax studies. The stability-enhanced analogs are relevant to research design (longer-acting probe compounds) but carry a separate, thinner evidence base at this time.
For N-Acetyl Semax Amidate variants compared to the parent compound, the key references are Shevchenko et al. 2013.[17][18] For the parent compound's pharmacokinetics, Shevchenko et al. 2006.[9]